# A Phase 1 Study of APX-343A as Monotherapy or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

> **NCT07123415** · PHASE1 · RECRUITING · sponsor: **Aptabio Therapeutics, Inc.** · enrollment: 110 (estimated)

## Conditions studied

- Advanced Solid Cancer
- Advanced Solid Tumor (Phase 1)

## Interventions

- **DRUG:** APX-343A
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT07123415
- **Lead sponsor:** Aptabio Therapeutics, Inc.
- **Sponsor class:** INDIV
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-24
- **Primary completion:** 2028-10
- **Final completion:** 2028-12
- **Target enrollment:** 110 (ESTIMATED)
- **Last updated:** 2025-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07123415

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07123415, "A Phase 1 Study of APX-343A as Monotherapy or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT07123415. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*